In an interview with Targeted Oncology, Lucio N. Gordan, MD, Florida Cancer Specialists & Research Institute, proposes a ...

Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...

Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...

Findings from a literature review recently published in The American Journal of Public Health suggest that greater ...

During a live event, Omid Hamid, MD, discussed the logistics and multidisciplinary process of using tumor-infiltrating ...

Segment 5 examines the patient’s response to first-line corticosteroids and uses it to discuss broader limitations of steroid ...

Segment 6 focuses on decision-making in second-line therapy for cGVHD, centering on the role of ruxolitinib. Dr. DeFilipp ...

Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...

Dr Gordan defines financial toxicity as the multifaceted economic burden arising from the total cost of care. In oncology, ...

The Immune Atlas identifies immune signatures in MM, enhancing outcome prediction and guiding personalized therapies by ...

BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous ...

Explore the complexities of HPV status in head and neck cancer treatment, emphasizing the importance of accurate patient ...